Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 216-220

  Dolman, M Emmy M ^a   den Hartog, Ilona J M ^a   Molenaar, Jan J ^a   Schellens, Jan H M ^b,c   Beijnen, Jos H ^b,c,d   Sparidans, Rolf W ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

AT7519; Cyclin dependent kinase inhibitor; LC MS MS; Mouse plasma

Indexed keywords

ACETONITRILE; AT 7519; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN; RUCAPARIB; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ARTICLE; CALIBRATION; CONTROLLED STUDY; DILUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROSPRAY; FEMALE; IONIZATION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MOUSE; NEUROBLASTOMA; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE; AT7519; AUC(0-∞); C(MAX); CDK; CYCLIN-DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR; EDTA; ELIMINATION HALF-LIFE; ETHYLENEDIAMINETETRAACETIC ACID; I.P.; INTERNAL STANDARD; INTRAPERITONEAL; IS; LC-MS/MS; MAXIMUM PLASMA CONCENTRATION; MOUSE PLASMA; MYCN; T(1/2); T(MAX); TIME TO C(MAX); V-MYC MYELOCYTOMATOSIS VIRAL RELATED ONCOGENE NEUROBLASTOMA DERIVED (AVIAN);

ANIMALS; CALIBRATION; CHROMATOGRAPHY, LIQUID; CYCLIN-DEPENDENT KINASES; FEMALE; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84884725467     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.08.051     Document Type: Article

References (11)

1. Sharp S.E., Gelfand M.J., Shulkin B.L. Pediatrics: diagnosis of neuroblastoma. Semin. Nucl. Med. 2011, 41:345-353.
2. Lodrini M., Oehme I., Schroeder C., Milde T., Schier M.C., Kopp-Schneider A., Schulte J.H., Fischer M., De Preter K., Pattyn F., Castoldi M., Muckenthaler M.U., Kulozik A.E., Westermann F., Witt O., Deubzer H.E. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013, 41:6018-6033.
3. Molenaar J.J., Ebus M.E., Geerts D., Koster J., Lamers F., Valentijn L.J., Westerhout E.M., Versteeg R., Caron H.N. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12968-12973.
4. Squires M.S., Feltell R.E., Wallis N.G., Lewis E.J., Smith D.M., Cross D.M., Lyons J.F., Thompson N.T. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol. Cancer Ther. 2009, 8:324-332.
5. Mahadevan D., Plummer R., Squires M.S., Rensvold D., Kurtin S., Pretzinger C., Dragovich T., Adams J., Lock V., Smith D.M., Von Hoff D., Calvert H. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann. Oncol. 2011, 22:2137-2143.
6. Center for Drug Evaluation and Research of the U.S.Department of Health and Human Services Food and Drug Administration Guidance for industry: Bioanalytical method validation 2001, (accessed 10.12.12). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm.
7. Lankheet N.A., Hillebrand M.J., Rosing H., Schellens J.H., Beijnen J.H., Huitema A.D. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed. Chromatogr. 2013, 27:466-476.
8. Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high-performance liquid chromatographic analysis. J. Chromatogr. 1981, 226:455-460.
9. European Medicines Agency Guideline on validation of bioanalytical methods 2009, (accessed 10.12.12). http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf.
10. Santo L., Vallet S., Hideshima T., Cirstea D., Ikeda H., Pozzi S., Patel K., Okawa Y., Gorgun G., Perrone G., Calabrese E., Yule M., Squires M., Ladetto M., Boccadoro M., Richardson P.G., Munshi N.C., Anderson K.C., Raje N. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010, 29:2325-2336.
11. Squires M.S., Cooke L., Lock V., Qi W., Lewis E.J., Thompson N.T., Lyons J.F., Mahadevan D. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 2010, 9:920-928.